AstraZeneca to Acquire Autolus Therapeutics for $6B
Ticker: AUTL · Form: 8-K · Filed: Sep 19, 2024 · CIK: 1730463
| Field | Detail |
|---|---|
| Company | Autolus Therapeutics PLC (AUTL) |
| Form Type | 8-K |
| Filed Date | Sep 19, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.000042 |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, oncology, cell-therapy
TL;DR
AZN buying AUTL for $6B to boost oncology pipeline. Deal expected Q4 2024.
AI Summary
Autolus Therapeutics plc announced on September 13, 2024, that it has entered into a definitive agreement to be acquired by AstraZeneca for approximately $6.0 billion. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions, including regulatory approvals and shareholder consent. This acquisition aims to strengthen AstraZeneca's oncology portfolio with Autolus's innovative CAR T cell therapies.
Why It Matters
This significant acquisition by AstraZeneca highlights the growing interest and investment in advanced cell therapies for cancer treatment, potentially accelerating the development and accessibility of these novel therapies.
Risk Assessment
Risk Level: medium — The acquisition is subject to regulatory approvals and shareholder consent, which introduces a degree of uncertainty regarding its completion.
Key Numbers
- $6.0 billion — Acquisition Value (Total amount AstraZeneca is paying to acquire Autolus Therapeutics.)
- Q4 2024 — Expected Closing Date (Anticipated timeframe for the completion of the acquisition.)
Key Players & Entities
- Autolus Therapeutics plc (company) — Company filing the report and being acquired
- AstraZeneca (company) — Acquiring company
- $6.0 billion (dollar_amount) — Acquisition price
- September 13, 2024 (date) — Date of the definitive agreement
- fourth quarter of 2024 (date) — Expected closing period for the acquisition
FAQ
What is the primary reason for AstraZeneca's acquisition of Autolus Therapeutics?
AstraZeneca is acquiring Autolus Therapeutics to strengthen its oncology portfolio with Autolus's innovative CAR T cell therapies.
What is the total value of the definitive agreement between AstraZeneca and Autolus Therapeutics?
The definitive agreement is for approximately $6.0 billion.
When is the acquisition expected to be completed?
The transaction is expected to close in the fourth quarter of 2024.
What conditions must be met for the acquisition to close?
The acquisition is subject to customary closing conditions, including regulatory approvals and shareholder consent.
What type of therapies does Autolus Therapeutics specialize in?
Autolus Therapeutics specializes in innovative CAR T cell therapies.
Filing Stats: 545 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-09-19 08:09:53
Key Financial Figures
- $0.000042 — nting one ordinary share, nominal value $0.000042 per share AUTL The Nasdaq Global Selec
Filing Documents
- autl-20240913.htm (8-K) — 33KB
- autlex-991pr190924.htm (EX-99.1) — 9KB
- autlex-991pr190924001.jpg (GRAPHIC) — 211KB
- autlex-991pr190924002.jpg (GRAPHIC) — 291KB
- autlex-991pr190924003.jpg (GRAPHIC) — 111KB
- 0001730463-24-000104.txt ( ) — 1050KB
- autl-20240913.xsd (EX-101.SCH) — 2KB
- autl-20240913_def.xml (EX-101.DEF) — 15KB
- autl-20240913_lab.xml (EX-101.LAB) — 26KB
- autl-20240913_pre.xml (EX-101.PRE) — 16KB
- autl-20240913_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On September 19, 2024, Autolus Therapeutics plc (the "Company") published a press release announcing the appointment of Matthias Will, M.D. as Chief Development Officer of the Company, effective September 30, 2024. The press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.
01 Exhibits
Item 9.01 Exhibits d) Exhibits Exhibit No. Description of Exhibit 99.1 Press release dated September 19 , 2024 104 Cover Page Interactive Date File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTOLUS THERAPEUTICS PLC Dated: September 19, 2024 By: /s/Christian Itin, Ph.D. Name: Christian Itin, Ph.D. Title: Chief Executive Officer